People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.0M | 2019 |
| Alphatec Holdings, Inc. | — | Other Health Care | Series C | $133.7M | $608.3M | 2017 |
| Tocagen Inc | — | Pharmaceuticals | Series C | $119.5M | $301.0M | 2023 |
| Palisade Bio, Inc. | — | Biotechnology | Series B | $57.3M | $30.4M | 2023 |
Donald Williams at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald Williams on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Foster | 1 | 10 |
| Hoyoung Huh | 1 | 7 |
| David Sidransky | 1 | 7 |
| Samir Patel | 1 | 7 |
| Kenneth Carter | 1 | 6 |
| JAMES HILL | 1 | 6 |
| James L.L. Tullis | 1 | 6 |
| MARK COHEN | 1 | 5 |
| John H. Foster | 1 | 4 |
| Scott Ogilvie | 1 | 4 |
| Yuval Cohen | 1 | 4 |
| Wendy DiCicco | 1 | 4 |
| Franklin M. Berger | 1 | 4 |
| Richard Daly | 1 | 3 |
| Johnson Lau | 1 | 3 |
| David H. Mowry | 1 | 3 |
| DAVID GRYSKA | 1 | 3 |
| Catherine Sohn | 1 | 3 |
| Jeffrey G. Black | 1 | 3 |
| DOV ELEFANT | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.